Literature DB >> 15800222

Learning the value of drugs--is rofecoxib a regulatory success story?

Rebecca S Eisenberg1.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2005        PMID： 15800222     DOI： 10.1056/NEJMp048358

Source DB:  PubMed          Journal:  N Engl J Med        ISSN： 0028-4793            Impact factor:   91.245


× No keyword cloud information.
  4 in total

1.  Preemption, tort reform, and pharmaceutical claims: Part two: Has the Food and Drug Administration shown it is solely responsible for the protection of patients? Can it do so? Will it do so?

Authors:  Russell G Thornton
Journal:  Proc (Bayl Univ Med Cent)       Date:  2008-01

2.  Evaluation of drug toxicity in clinical trials.

Authors:  J Splawinski; J Kuzniar; K Filipiak; W Zielinski
Journal:  Sci Eng Ethics       Date:  2006-01       Impact factor: 3.525

3.  Price regulation, new entry, and information shock on pharmaceutical market in Taiwan: a nationwide data-based study from 2001 to 2004.

Authors:  Fei-Yuan Hsiao; Yi-Wen Tsai; Weng-Foung Huang
Journal:  BMC Health Serv Res       Date:  2010-07-25       Impact factor: 2.655

4.  Getting it right: being smarter about clinical trials.

Authors:  Barnett S Kramer; Joan Wilentz; Duane Alexander; John Burklow; Lawrence M Friedman; Richard Hodes; Ruth Kirschstein; Amy Patterson; Griffin Rodgers; Stephen E Straus
Journal:  PLoS Med       Date:  2006-04       Impact factor: 11.069
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.